Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Standard
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. / Goette, Andreas; Schön, Norbert; Kirchhof, Paulus; Breithardt, Günter; Fetsch, Thomas; Häusler, Karl Georg; Klein, Helmut U; Steinbeck, Gerhard; Wegscheider, Karl; Meinertz, Thomas.
In: CIRC-ARRHYTHMIA ELEC, Vol. 5, No. 1, 1, 2012, p. 43-51.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
AU - Goette, Andreas
AU - Schön, Norbert
AU - Kirchhof, Paulus
AU - Breithardt, Günter
AU - Fetsch, Thomas
AU - Häusler, Karl Georg
AU - Klein, Helmut U
AU - Steinbeck, Gerhard
AU - Wegscheider, Karl
AU - Meinertz, Thomas
PY - 2012
Y1 - 2012
N2 - Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.
AB - Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Prospective Studies
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Time Factors
KW - Incidence
KW - Double-Blind Method
KW - Dose-Response Relationship, Drug
KW - Germany/epidemiology
KW - Angiotensin II Type 1 Receptor Blockers/administration & dosage
KW - Atrial Fibrillation/drug therapy/epidemiology/physiopathology
KW - Electrocardiography/drug effects
KW - Imidazoles/administration & dosage
KW - Tachycardia, Paroxysmal/drug therapy/epidemiology/physiopathology
KW - Tetrazoles/administration & dosage
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Prospective Studies
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Time Factors
KW - Incidence
KW - Double-Blind Method
KW - Dose-Response Relationship, Drug
KW - Germany/epidemiology
KW - Angiotensin II Type 1 Receptor Blockers/administration & dosage
KW - Atrial Fibrillation/drug therapy/epidemiology/physiopathology
KW - Electrocardiography/drug effects
KW - Imidazoles/administration & dosage
KW - Tachycardia, Paroxysmal/drug therapy/epidemiology/physiopathology
KW - Tetrazoles/administration & dosage
M3 - SCORING: Journal article
VL - 5
SP - 43
EP - 51
JO - CIRC-ARRHYTHMIA ELEC
JF - CIRC-ARRHYTHMIA ELEC
SN - 1941-3149
IS - 1
M1 - 1
ER -